
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics Inc. is projected to generate approximately $32 million in top-line revenue for 2025, with expectations of a significant increase to $130.4 million by 2026, indicating strong growth potential. The favorable market access situation suggests that coverage for its gene therapies and plasma-based products is likely to improve, which may drive additional revenue upside. Furthermore, the company's promising pipeline assets, specifically its innovative gene therapies targeting rare genetic diseases, may further enhance the positive outlook on its financial performance.
Bears say
Abeona Therapeutics Inc. faces significant risks that negatively impact its outlook, particularly the potential for slower-than-expected market uptake of its engineered cell therapy, pz-cel, in the United States. The company's challenges extend to its inability to maximize the value of pz-cel outside the U.S., which could hinder revenue growth. Furthermore, setbacks in earlier-stage pipeline programs and the prospect of long-term dilution add additional layers of uncertainty to the financial viability of the company.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares